|
WO2021072535A1
|
|
Oil-in-water emulsion formulations for delivery of active or therapeutic agents
|
|
WO2020104923A1
|
|
Methods for improving the efficacy of a survivin therapeutic in the treatment of tumors
|
|
EP3768242A1
|
|
Methods and compositions for targeted delivery of active agents and immunomodulatory agents to lymph nodes
|
|
JP2018070629A
|
|
Method for improving efficacy of survivin vaccine in treatment of cancer
|
|
US2020353062A1
|
|
Pharmaceutical compositions, methods for preparation comprising sizing of lipid vesicle particles, and uses thereof
|
|
EP3651733A1
|
|
Pharmaceutical compositions, methods for preparation using lipid vesicle particles of defined size, and uses thereof
|
|
US2019151428A1
|
|
Vaccine Compositions Comprising an Amphipathic Compound, a Neoantigen and a Hydrophobic Carrier, and Methods of Use Thereof
|
|
EP3377099A1
|
|
Adjuvanting systems and water-free vaccine compositions comprising a polyi:c polynucleotide adjuvant and a lipid-based adjuvant
|
|
WO2018058230A1
|
|
Methods of using low dose volume b-cell epitope compositions for inducing an antibody immune response in human subjects
|
|
WO2016176761A1
|
|
Methods for potentiating an immune response using depot-forming and non-depot-forming vaccines
|
|
CA2972635A1
|
|
Lipid a mimics, methods of preparation, and uses thereof
|
|
EP2978450A1
|
|
Method for improving the efficacy of a survivin vaccine in the treatment of cancer
|
|
AU2012321022A1
|
|
Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof
|
|
AU2009253780A1
|
|
Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
|
|
AU2008307042A1
|
|
Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
|
|
US2010209452A1
|
|
Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
|
|
CN106310293A
|
|
Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
|
|
CA2523032A1
|
|
Vaccines for cancer therapy
|
|
US7056515B2
|
|
Antigens for immunocontraception
|
|
AU2003244428A1
|
|
Antigens for immunocontraception
|
